{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:29:22Z","timestamp":1791980962192,"version":"4.4.0"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Anidulafungin is a novel semisynthetic echinocandin with potent activity against<jats:italic>Candida<\/jats:italic>(including azole-resistant isolates) and<jats:italic>Aspergillus<\/jats:italic>spp. and is used for serious systemic fungal infections. The purpose of these studies was to characterize the clearance mechanism and potential for drug interactions of anidulafungin. Experiments included in vitro degradation of anidulafungin in buffer and human plasma, a bioassay for antifungal activity, in vitro human cytochrome P450 inhibition studies, in vitro incubation with rat and human hepatocytes, and mass balance studies in rats and humans. Clearance of anidulafungin appeared to be primarily due to slow chemical degradation, with no evidence of hepatic-mediated metabolism (phase 1 or 2). Under physiological conditions, further degradation of the primary degradant appears to take place. The primary degradation product does not retain antifungal activity. Anidulafungin was not an inhibitor of cytochrome P450 enzymes commonly involved in drug metabolism. Mass balance studies showed that anidulafungin was eliminated in the feces predominantly as degradation products, with only a small fraction (10%) eliminated as unchanged drug; fecal elimination likely occurred via biliary excretion. Only negligible renal involvement in the drug's elimination was observed. In conclusion, the primary biotransformation of anidulafungin is mediated by slow chemical degradation, with no evidence for hepatic enzymatic metabolism or renal elimination.<\/jats:p>","DOI":"10.1128\/aac.01279-08","type":"journal-article","created":{"date-parts":[[2008,11,25]],"date-time":"2008-11-25T02:07:08Z","timestamp":1227578828000},"page":"1149-1156","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":64,"title":["In Vitro and In Vivo Studies To Characterize the Clearance Mechanism and Potential Cytochrome P450 Interactions of Anidulafungin"],"prefix":"10.1128","volume":"53","author":[{"given":"Bharat D.","family":"Damle","sequence":"first","affiliation":[{"name":"Pfizer Inc., New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Dowell","sequence":"additional","affiliation":[{"name":"Vicuron Pharmaceuticals, Subsidiary of Pfizer Inc., New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Walsky","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Weber","sequence":"additional","affiliation":[{"name":"Pfizer Inc., St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stogniew","sequence":"additional","affiliation":[{"name":"Vicuron Pharmaceuticals, Subsidiary of Pfizer Inc., New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip B.","family":"Inskeep","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Mycamine (micafungin sodium) for injection 2008"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0090-9556(24)15072-6","volume":"28","year":"2000","unstructured":"Balani, S. K., X. Xu, B. H. Arison, M. V. Silva, A. Gries, F. A. DeLuna, D. Cui, P. H. Kari, T. Ly, C. E. Hop, R. Singh, M. A. Wallace, D. C. Dean, J. H. Lin, P. G. Pearson, and T. A. Baillie. 2000. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab. Dispos.28:1274-1278.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01596-07"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00507-2"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14472-8"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0091270006297227","volume":"47","year":"2007","unstructured":"Dowell, J. A., M. Stogniew, D. Krause, and B. Damle. 2007. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J. Clin. Pharmacol.47:461-470.","journal-title":"J. Clin. Pharmacol."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006296764"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005281234"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004270146"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004265644"},{"key":"e_1_3_2_12_2","unstructured":"ECALTA: summary of product characteristics 2007"},{"key":"e_1_3_2_13_2","first-page":"473","year":"1995","unstructured":"Guengerich, F. P. 1995. Human cytochrome P450 enzymes, p. 473-535. In P. R. Ortiz de Montellano (ed.), Cytochrome P450: structure, mechanism, and biochemistry, 2nd ed. Plenum Press, New York, NY.","journal-title":"Cytochrome P450: structure, mechanism, and biochemistry"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005279580"},{"key":"e_1_3_2_15_2","unstructured":"Plasma protein binding of anidulafungin is similar to other major echinocandins 2008"},{"key":"e_1_3_2_16_2","unstructured":"Lack of anidulafungin interactions with CYP enzymes and transporters in in vivo and in vitro systems 2008"},{"key":"e_1_3_2_17_2","first-page":"94","volume":"50","year":"2002","unstructured":"Kaneko, H., Y. Yamato, T. Hashimoto, I. Ishii, T. Shiragami, A. Kawamura, M. Terakawa, and A. Kagayama. 2002. Drug interactions of micafungin in vitro. Jpn. J. Chemother.50(Suppl. 1):94-103. [In Japanese.]","journal-title":"Jpn. J. Chemother."},{"key":"e_1_3_2_18_2","first-page":"1","volume":"50","year":"2002","unstructured":"Kohno, S., and H. Yamaguchi. 2002. Overview of micafungin (MCFG). Jpn. J. Chemother.50(Suppl. 1):1-7. [In Japanese.]","journal-title":"Jpn. J. Chemother."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0026-895X(25)09118-7","volume":"36","year":"1989","unstructured":"Kronbach, T., D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer. 1989. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol.36:89-96.","journal-title":"Mol. Pharmacol."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0003-2697(87)90006-6","volume":"162","year":"1987","unstructured":"Kronbach, T., D. Mathys, G. Gut, T. Catin, and U. A. Meyer. 1987. High-performance liquid chromatographic assays for bufuralol l1-hydroxylase debrisquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal. Biochem.162:24-32.","journal-title":"Anal. Biochem."},{"key":"e_1_3_2_21_2","first-page":"29","volume":"52","year":"1992","unstructured":"Leemann, T., C. Transon, and P. Dayer. 1992. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4\u2032hydroxylation in human liver. Life Sci.52:29-34.","journal-title":"Life Sci."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.696-700.2001"},{"key":"e_1_3_2_23_2","unstructured":"Cancidas (caspofungin acetate) for injection 2008"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199708000-00013"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3149-3154.2003"},{"key":"e_1_3_2_26_2","unstructured":"Eraxis (anidulafungin) for injection 2007"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/14787210.2.4.499","volume":"2","year":"2004","unstructured":"Raasch, R. H. 2004. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev. Anti. Infect. Ther.2:499-508.","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.003244"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1272-1280.2004"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4306-4314.2004"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.815-823.2004"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)85039-1"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0022-3565(25)38136-X","volume":"265","year":"1993","unstructured":"Tassaneeyakul, W., D. J. Birkett, M. E. Veronese, M. E. Mcmanus, R. H. Tukey, L. C. Quattrochi, H. V. Gelboin, and J. O. Minors. 1993. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther.265:401-407.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_34_2","unstructured":"Anidulafungin: a phase I study to identify the maximum tolerated dose in healthy volunteers 2001"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1016\/S0021-9258(19)42253-9","volume":"249","year":"1974","unstructured":"Van der Hoeven, T. A., and M. J. Coon. 1974. Preparation and properties of partially purified cytochrome P 450 and reduced nicotinamide-adenine dinucleotide phosphate-cytochrome P 450 reductase from rabbit liver microsomes. J. Biol. Chem.249:6302-6310.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.104.002766","volume":"33","year":"2005","unstructured":"Walsky, R. L., R. S. Obach, E. A. Gaman, J.-P. R. Gleeson, and W. R. Proctor. 2005. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab. Dispos.33:413-418.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","volume":"32","year":"2004","unstructured":"Walsky, R. L., and R. S. Obach. 2004. Validated assays for human cytochrome P450 activities. Drug Metab. Dispos.32:647-660.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF02353474","volume":"24","year":"1996","unstructured":"Wrighton, S. A., M. VandenBranden, and B. J. Ring. 1996. The human drug metabolizing cytochromes P450. J. Pharmacokinet. Biopharm.24:461-473.","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/019262339502300214","volume":"23","year":"1995","unstructured":"Wrighton, S. A., B. J. Ring, and M. VandenBranden. 1995. The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicol. Pathol.23:199-208.","journal-title":"Toxicol. Pathol."},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408449209145319","volume":"22","year":"1992","unstructured":"Wrighton, S. A., and J. C. Stevens. 1992. The human hepatic cytochrome P450 involved in drug metabolism. Crit. Rev. Toxicol.22:1-21.","journal-title":"Crit. Rev. Toxicol."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01279-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01279-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T15:34:56Z","timestamp":1738683296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01279-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1128\/AAC.01279-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.01279-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"2008-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-11-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}